A New Phase in
Cell Delivery
A droplet-based cell delivery system for biological cargos
-
Unlocking New Applications
BubbleFect enables safe, efficient intracellular delivery of biologics such RNA, DNA, and proteins, without the toxicity, formulation complexity, or cold chain requirements of lipid nanoparticles (LNPs).
BubbleFect spontaneously co-assembles your cargoes of interest in physiologically relevant cell culture medium, allowing you to rapidly dream up multi-component experiments that are out of reach with other transfection methods. So whether you are an academic lab, biotech startup, CRO or pharma company, you will be able to use our plug-and-play bubbles to accelerate your research and therapeutic development -
Gentle on cells
Compared to electroporation, which requires expensive equipment, precise calibration, and can damage cells through electrical shock, BubbleFect offers a gentle, easy-to-use alternative for intracellular delivery. Ideal for academic labs, biotech startups, and pharma teams seeking to accelerate research and therapeutic development.
BubbleFect’s aqueous natural peptide-inspired formulation also ensures a milder cell delivery than lipid-based or polymeric delivery systems that interfere with cell membranes and show cytotoxicity phenotypes -
Room-Temperature Stability
Viral vectors, such as AAV or lentivirus, are widely used for gene delivery but require ultra-cold storage and complex manufacturing, posing significant logistical and cost challenges. In contrast, BubbleFect is a room-temperature stable platform. It’s on-demand, decentralised delivery of therapeutics, making it a more agile and sustainable solution for next-generation biologics.
About PartitionBio
PartitionBio is tackling one of the biggest challenges in modern medicine: the safe, efficient, and affordable delivery of genetic medicines and complex biologics, like RNA, DNA and protein therapies, into human cells. Traditional delivery methods, especially viral vectors, are costly, complex to manufacture, and pose potential safety risks. These barriers limit access to cutting-edge therapies, particularly in low- and middle-income countries (LMICs), where healthcare infrastructure and budgets are constrained.
PartitionBio’s innovative solution uses engineered biocondensates, which are natural, membrane-less structures within cells, to create a non-viral delivery system. These condensates can shuttle therapeutic macromolecules directly into cells, bypassing the need for viral packaging or expensive lipid nanoparticles.
By solving this bottleneck in gene therapy delivery, PartitionBio enables:
Lower production costs, making treatments more accessible
Improved safety profiles, with reduced immune response risks
Scalability, ideal for widespread use in global health settings
For patients, this translates to broader access to life-changing treatments, from rare genetic disorders to chronic diseases and in regions where such care was previously unavailable. PartitionBio’s platform has the potential to democratise advanced medicine, delivering powerful therapies not just to the privileged few, but to communities worldwide.
Time to Rethink Intracellular Delivery: Why the Market Needs Disruption
It’s time to disrupt the delivery bottleneck. Unlocking the full potential of next-generation biologics starts with better ways to get them where they need to go: inside the cell.
Biologic therapies, like mRNA, gene editing, and protein drugs, are transforming modern medicine. But while the science has moved forward, cell delivery methods haven’t kept up.
Traditional tools like viral vectors, lipid nanoparticles, and electroporation come with serious trade-offs: toxicity, limited targeting, cold chain requirements, and high costs. These challenges slow down discovery, limit clinical applications, and make global access harder.
As therapies become more complex and personalised, we need delivery platforms that are scalable, flexible, and easy to use, across labs, clinics, and geographies. Importantly, they must be safe and sustainable, supporting repeat dosing and room-temperature logistics.
The solution lies in a completely new technology inspired by liquid-liquid phase separation (LLPS), a natural biological process where biomolecules spontaneously form distinct, membraneless compartments or droplets inside cells and in vitro. This “phase” approach enables precise sorting and enrichment of biologic cargo within biocompatible aqueous droplets, creating highly efficient, cell-and cargo-friendly delivery systems that overcome many limitations of traditional methods.
It’s not just new, it’s fresh.
Introducing BubbleFect:
Smarter Delivery for
Modern Biologics
As RNA, DNA, and protein therapies continue to reshape medicine, one challenge remains: how to deliver them safely and effectively into cells.
Traditional delivery methods, like viral vectors, lipid nanoparticles, and electroporation, often fall short. They can be toxic, costly, complex, and limited in where and how they work. For next-generation biologics to reach their full potential, we need something better.
That’s why we developed BubbleFect, a non-viral, room-temperature stable delivery platform designed for simplicity, scalability, and versatility. It enables efficient intracellular delivery without the trade-offs: no cold chain, no complex hardware, and no compromising cell viability.
BubbleFect fits seamlessly into existing lab workflows and is already being adopted across early-stage research and development programs through our Alpha Program. It’s designed to grow with your science, from discovery to clinical translation.
It’s time for delivery to catch up with therapy.
BubbleFect makes that possible.
Alpha Program. How it works.
-
When you join the FREE BubbleFect Alpha Program we set up a quick call to explore how our delivery technology can accelerate your research and answer questions about your application. We will take a few simple details like name, address, VAT number and prefered delivery date to send you your free BubbleFect*.
-
Using BubbleFect is refreshingly simple. Just mix your biological cargo, whether it's RNA, DNA, or protein, with BubbleFect reagent in water. Then, add your standard physiological buffer (e.g. PBS or cell culture medium) to set off the spontaneous bubble reaction, making it instantaneously ready to add to your cells!
-
A typical BubbleFect experiment fits easily into your standard lab schedule. After mixing your cargo with water and adding the BubbleFect reagent, add physiological buffer to get your formulation ready in minutes. Simply apply it to your cells and incubate, no media change or special handling required. Depending on your assay, you can begin to see results in as little as 4 to 24 hours, whether you're tracking fluorescent protein expression, mRNA translation, or functional protein activity. Readouts can be observed via microscopy, flow cytometry, or standard plate-based assays, making integration seamless with your existing workflows.
-
At PartitionBio, we’re committed to supporting your success every step of the way. After you’ve had time to run your experiment with BubbleFect, our team will check in to hear about your results, answer any questions, and discuss how the platform performed in your specific application. We’re eager to explore opportunities for further experiments, optimisations, or potential collaborations to help you maximise the impact of your research. Your feedback guides our development, and together we can advance innovative solutions tailored to your scientific goals.
* while stocks last
Applications: Unlocking Therapeutic Potential
mRNA Therapeutics Delivery
PartitionBio applies its expertise in biomolecular condensates to unlock safer, more efficient delivery of mRNA therapeutics. By leveraging LLPS principles, we enable dynamic, compartmentalised delivery systems, like BubbleFect, that enhance mRNA stability, translation efficiency, and intracellular targeting. This approach reduces reliance on complex cold chains and toxic carriers, helping mRNA therapies scale from lab to clinic with greater flexibility and reach.
Gene Editing and CRISPR Modulation
Using LLPS-driven delivery systems, PartitionBio supports precise, non-viral intracellular delivery of CRISPR-Cas components. Thanks to the ability to mix-and-match cargo types, BubbleFect users will have the opportunity to explore the delivery of gene editing complexes as an RNP, which is an approach that is reported to reduce off-target editing.
Protein and Enzyme Replacement Therapies
PartitionBio’s phase separation technology provides a unique route for delivering fully folded, functional proteins directly into cells. This enables real-time modulation of intracellular pathways, enzyme replacement in genetic disorders, intracellular antibody delivery, and novel therapeutic strategies that bypass transcription altogether. The result is efficient, gentle intracellular access that maintains protein integrity and cell viability.
Advanced Research Tools and Cell Engineering
By rethinking how molecules are packaged and delivered, using LLPS principles, PartitionBio empowers researchers to engineer cells more effectively. Whether for functional genomics, high-throughput screening, or therapeutic cell line development, our platforms simplify the delivery of nucleic acids and proteins across a wide range of cell types, enabling faster results without the need for specialised equipment or protocols.
Supporting Data: See the Science
eGFP mRNA expression in non-dividing terminally differentiated muscle myotube cells
In comparative studies, BubbleFect demonstrated a significant improvement in transfection efficiency, increasing the reporter protein level to ten times higher than that achieved by a leading lipid-based competitor under identical conditions. This increase in yield reflects the higher payload delivery that is possible with BubbleFect, with minimal toxicity or disruption to cell health. The result is superior performance, especially in applications requiring high expression levels, broader cell coverage, or sensitive cell types. BubbleFect’s efficient, reagent-only workflow also makes it easier to reproduce these results across labs and experiments.
NEED OTHER DATA GRAPH!
WHAT ARE WE SEEING?
WHY IS IT COOL?
It’s not just new, it’s fresh.
The Team
Founder and Chairman of PartitionBio
Niall Armes is the scientific founder of PartitionBio and a renowned molecular biologist and protein biochemist. He invented Recombinase Polymerase Amplification (RPA), a widely used isothermal DNA amplification technology central to Illumina sequencing.
He is also the founder and Chief Scientific Officer of Biocrucible, a UK-based subsidiary of Sapphiros, developing novel amplification chemistries for rapid, low-cost diagnostics.
A pioneer in biomolecular condensates, Niall was the first to construct an in vitro multi-enzyme machine via crowding-driven condensation. This foundational work led to the creation of PartitionBio, aimed at leading synthetic biology innovations through engineered phase separation and targeted drug delivery.
As CEO of TwistDX, he led a $160M exit to Alere (later acquired by Abbott). In 2021, he sold Biocrucible to KKR’s diagnostics venture Sapphiros, joined its board, and spun out non-diagnostic IP into PartitionBio.
Niall holds over 33 U.S. patents, with a BSc from Newcastle University and a PhD in Molecular Biology from the Imperial Cancer Research Fund (now CRUK).
Managing Director of PartitionBio
Between 2003 and 2018 he worked with Niall Armes as Chief Scientific Officer of TwistDx Ltd on the development and commercialisation of the Recombinase Polymerase Amplification (RPA) technology.
RPA, the leading isothermal nucleic acid amplification approach, is fundamentally based on the dramatic increase of in vitro enzymatic activities in appropriately configured molecular condensates.
Following his involvement with TwistDx, Olaf worked in senior positions in the private biotechnology sector (Head of Sequencing Biochemistry at Base4 Ltd, Head of Molecular Development at SenseBio Ltd), before joining the Scientific Operations department at the Wellcome Sanger Institute in Hinxton, UK as Head of Research.
Olaf obtained his PhD in Molecular Genetics at the Max-Planck-Institute for Biophysical Chemistry in Göttingen, Germany and he completed post-doctoral studies with Sir Jim Smith at the Gurdon Institute in Cambridge, UK.
Head of Business Development & Scientific Partnerships at PartitionBio
Zehra Nizami is a biotech scientist and translational strategist working at the nexus of scientific discovery and real-world application. As Head of Business Development & Scientific Partnerships and Principal Scientist at PartitionBio, she leads external strategy and collaborations to advance BubbleFect, the company’s non-viral delivery platform, for research and therapeutic use.
Her scientific journey began at Princeton University, researching B cell tolerance in autoimmune disease. During her PhD and postdoc at Johns Hopkins/Carnegie, Zehra made foundational contributions to the study of biomolecular condensates, discovering new nuclear organelles and non-coding RNAs involved in nuclear architecture and gene regulation.
That work sparked a career-long focus on RNA biology and cellular compartmentalisation, leading to BubbleFect, a delivery system inspired by nature’s own compartments to efficiently transport RNA, DNA, CRISPR, and proteins. This platform anchors a broader therapeutic pipeline based on leveraging endogenous condensates.
Director & Chief Operations Officer at PartitionBio
Helen brings over 35 years of experience in the life sciences and biotech sectors, with 25+ years in senior operational leadership. She served as Chief Operations Officer (COO) at TwistDx, overseeing R&D and production operations for the company's RPA isothermal amplification technology, including facilities development, H&S implementation, ERP systems, and ISO 13485 compliance.
Helen later became COO and Director at Biocrucible, where she led business systems implementation, site expansion, ERP upgrades, HR, and H&S, supporting the company through its acquisition by Sapphiros Inc and the subsequent spin-out of PartitionBio.
She currently serves as COO and Director at PartitionBio, building out operational systems for the growing biotech startup, and since 2022, has also held the role of COO at Gene Weaver, based at Chesterford Research Park.
Follow our Journey
